Table 2.
Results for baseline, week 4 and week 16
| Control group | Fish oil group | |||||
|---|---|---|---|---|---|---|
|
Week 0 (BP) (n = 13) |
Week 4 (P) (n = 13) |
Week 16 (PX) (n = 13) |
Week 0 (BF) (n = 16) |
Week 4 (FO) (n = 14) |
Week 16 (FOX) (n = 14) |
|
| Age (y) | 56.2 ± 1.3 | 49.2 ± 2.0d | ||||
| BMI (kg/m2) | 31.9 ± 1.3 | 31.9 ± 1.2 | 31.6 ± 1.2 | 32.5 ± 0.8 | 32.6 ± 0.8 | 32.3 ± 0.9 |
| UC (cm) | 112.8 ± 2.5 | 111.6 ± 2.2 | 111.4 ± 2.7 | 110.1 ± 1.8 | 108.9 ± 1.7 | 108.2 ± 1.8 |
| Fasting results | ||||||
| Fasting glucose (mmol/L) | 6.49 ± 0.62 | 6.54 ± 0.73 | 6.38 ± 0.54 | 6.50 ± 0.15 | 6.89 ± 0.88d | 6.66 ± 0.87 |
| HOMA | 3.37 ± 0.42 | 3.35 ± 0.40 | 3.09 ± 0.38 | 3.60 ± 0.34 | 4.29 ± 0.50a | 3.27 ± 0.35c |
| Fasting TAG (mmol/L) | 1.85 ± 0.24 | 1.97 ± 0.27 | 1.85 ± 0.21 | 1.69 ± 0.15 | 1.67 ± 0.14 | 1.31 ± 0.08b, c, d |
| Fasting Total-C (mmol/L) | 5.36 ± 0.25 | 5.60 ± 0.19 | 5.41 ± 0.29 | 5.25 ± 0.16 | 5.40 ± 0.17 | 5.24 ± 0.20 |
| Fasting LDL-C (mmol/L) | 3.55 ± 0.23 | 3.67 ± 0.16 | 3.49 ± 0.20 | 3.39 ± 0.17 | 3.68 ± 0.17a | 3.60 ± 0.20 |
| Fasting HDL-C (mmol/L) | 0.92 ± 0.05 | 1.02 ± 0.04a | 1.06 ± 0.05b | 1.00 ± 0.03 | 0.96 ± 0.04 | 1.04 ± 0.04c |
| Fasting apo B-48 (mg/L) | 10.96 ± 1.20 | 11.12 ± 1.18 | 10.56 ± 1.11 | 9.91 ± 0.63 | 10.17 ± 0.92 | 8.51 ± 0.82b |
| Postprandial results | ||||||
| TAG IAUC (mmol/L/9 h) | 9.0 ± 0.8 | 10.1 ± 1.1 | 9.0 ± 1.0 | 9.4 ± 1.0 | 7.7 ± 1.0a, d | 6.0 ± 0.8b, c, d |
| Apo B48 IAUC (mg/L/9 h) | 13.2 ± 2.2 | 12.5 ± 2.0 | 14.4 ± 2.0 | 15.1 ± 2.0 | 13.4 ± 2.4 | 14.8 ± 1.9 |
Results are mean ± SE.
Within group differences as indicated; week 4 v. week 0 a; week 16 v. week 0 b; week 16 v. 4 c. Between group differences placebo v. FO same week d